Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Weighted Average) (2023 - 2025)

CG Oncology filings provide 3 years of Shares Outstanding (Weighted Average) readings, the most recent being $77.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 23.69% to $77.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $77.3 million, a 23.69% increase, with the full-year FY2025 number at $77.3 million, up 23.69% from a year prior.
  • Shares Outstanding (Weighted Average) hit $77.3 million in Q4 2025 for CG Oncology, up from $76.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $77.3 million in Q4 2025 to a low of $3.9 million in Q1 2023.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $61.4 million (2024), compared with a mean of $46.6 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 1615.24% in 2024 and later rose 14.34% in 2025.
  • CG Oncology's Shares Outstanding (Weighted Average) stood at $4.3 million in 2023, then soared by 1343.03% to $62.5 million in 2024, then grew by 23.69% to $77.3 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $77.3 million (Q4 2025), $76.7 million (Q3 2025), and $76.2 million (Q2 2025) per Business Quant data.